# ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

> **NCT03362190** · PHASE2 · COMPLETED · sponsor: **Ophthotech Corporation** · enrollment: 64 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Avacincaptad Pegol
- **DRUG:** Lucentis

## Key facts

- **NCT ID:** NCT03362190
- **Lead sponsor:** Ophthotech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-11
- **Primary completion:** 2018-10-18
- **Final completion:** 2018-10-18
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03362190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03362190, "ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03362190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*